Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 3361 to 3365 of 3365 entries
Sorted by: Best Match Show Resources per page
Ferrihydrite Reduction by Photosynthetic .

Frontiers in microbiology

Tanaka K, Shimakawa G, Kusama S, Harada T, Kato S, Nakanishi S.
PMID: 33763051
Front Microbiol. 2021 Mar 08;12:650832. doi: 10.3389/fmicb.2021.650832. eCollection 2021.

Microbial extracellular electron transfer (EET) to solid-state electron acceptors such as anodes and metal oxides, which was originally identified in dissimilatory metal-reducing bacteria, is a key process in microbial electricity generation and the biogeochemical cycling of metals. Although it...

Cite
Tanaka K, Shimakawa G, Kusama S, et al. Ferrihydrite Reduction by Photosynthetic . Front Microbiol. 2021;12:650832doi: 10.3389/fmicb.2021.650832.
Tanaka, K., Shimakawa, G., Kusama, S., Harada, T., Kato, S., & Nakanishi, S. (2021). Ferrihydrite Reduction by Photosynthetic . Frontiers in microbiology, 12650832. https://doi.org/10.3389/fmicb.2021.650832
Tanaka, Kenya, et al. "Ferrihydrite Reduction by Photosynthetic ." Frontiers in microbiology vol. 12 (2021): 650832. doi: https://doi.org/10.3389/fmicb.2021.650832
Tanaka K, Shimakawa G, Kusama S, Harada T, Kato S, Nakanishi S. Ferrihydrite Reduction by Photosynthetic . Front Microbiol. 2021 Mar 08;12:650832. doi: 10.3389/fmicb.2021.650832. eCollection 2021. PMID: 33763051; PMCID: PMC7982531.
Copy Download .nbib Format: NLM
Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.

Investigational new drugs

Omori S, Harada H, Mori K, Hisamatsu Y, Tsuboguchi Y, Yoshioka H, Morinaga R, Daga H, Kurata T, Takahashi T.
PMID: 34495421
Invest New Drugs. 2022 Feb;40(1):106-114. doi: 10.1007/s10637-021-01155-w. Epub 2021 Sep 08.

Few clinical studies have been designed for elderly patients with locally advanced non-small cell lung cancer (NSCLC). We conducted a phase I study to evaluate the tolerability of carboplatin/nab-paclitaxel and concurrent thoracic radiotherapy in elderly patients with locally advanced...

Cite
Omori S, Harada H, Mori K, et al. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Invest New Drugs. 2021;40(1):106-114doi: 10.1007/s10637-021-01155-w.
Omori, S., Harada, H., Mori, K., Hisamatsu, Y., Tsuboguchi, Y., Yoshioka, H., Morinaga, R., Daga, H., Kurata, T., & Takahashi, T. (2022). Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Investigational new drugs, 40(1), 106-114. https://doi.org/10.1007/s10637-021-01155-w
Omori, Shota, et al. "Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer." Investigational new drugs vol. 40,1 (2022): 106-114. doi: https://doi.org/10.1007/s10637-021-01155-w
Omori S, Harada H, Mori K, Hisamatsu Y, Tsuboguchi Y, Yoshioka H, Morinaga R, Daga H, Kurata T, Takahashi T. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Invest New Drugs. 2022 Feb;40(1):106-114. doi: 10.1007/s10637-021-01155-w. Epub 2021 Sep 08. PMID: 34495421.
Copy Download .nbib Format: NLM
A case of subfertile cow with structural abnormalities of the X-chromosome.

Annales de genetique et de selection animale

Hanada H, Muramatsu S.
PMID: 22896164
Ann Genet Sel Anim. 1980;12(2):209-13. doi: 10.1186/1297-9686-12-2-209.

No abstract available.

Cite
Hanada H, Muramatsu S. A case of subfertile cow with structural abnormalities of the X-chromosome. Ann Genet Sel Anim. 1980;12(2):209-13doi: 10.1186/1297-9686-12-2-209.
Hanada, H., & Muramatsu, S. (1980). A case of subfertile cow with structural abnormalities of the X-chromosome. Annales de genetique et de selection animale, 12(2), 209-13. https://doi.org/10.1186/1297-9686-12-2-209
Hanada, H, and Muramatsu, S. "A case of subfertile cow with structural abnormalities of the X-chromosome." Annales de genetique et de selection animale vol. 12,2 (1980): 209-13. doi: https://doi.org/10.1186/1297-9686-12-2-209
Hanada H, Muramatsu S. A case of subfertile cow with structural abnormalities of the X-chromosome. Ann Genet Sel Anim. 1980;12(2):209-13. doi: 10.1186/1297-9686-12-2-209. PMID: 22896164; PMCID: PMC2718867.
Copy Download .nbib Format: NLM
Impact of the Concomitant Use of Immunomodulator and a Lower Week 8 Partial Mayo Score on the Persistence of Adalimumab in Refractory Ulcerative Colitis.

Internal medicine (Tokyo, Japan)

Kumei S, Sakurai T, So S, Itaba S, Akiho H, Nakamura S, Kim H, Yamasaki M, Takatsu N, Maekawa R, Sakemi R, Watanabe T, Shibata M, Kume K, Yoshikawa I, Takaki Y, Harada M.
PMID: 34121007
Intern Med. 2021 Dec 15;60(24):3849-3856. doi: 10.2169/internalmedicine.7279-21. Epub 2021 Jun 12.

Objective Real-world data of adalimumab (ADA) in the treatment of ulcerative colitis (UC) are scarce. We aimed to study the ADA response rates and predictors of response in UC treatment. Methods This observational, prospective and multi-center study assessed the...

Cite
Kumei S, Sakurai T, So S, et al. Impact of the Concomitant Use of Immunomodulator and a Lower Week 8 Partial Mayo Score on the Persistence of Adalimumab in Refractory Ulcerative Colitis. Intern Med. 2021;60(24):3849-3856doi: 10.2169/internalmedicine.7279-21.
Kumei, S., Sakurai, T., So, S., Itaba, S., Akiho, H., Nakamura, S., Kim, H., Yamasaki, M., Takatsu, N., Maekawa, R., Sakemi, R., Watanabe, T., Shibata, M., Kume, K., Yoshikawa, I., Takaki, Y., & Harada, M. (2021). Impact of the Concomitant Use of Immunomodulator and a Lower Week 8 Partial Mayo Score on the Persistence of Adalimumab in Refractory Ulcerative Colitis. Internal medicine (Tokyo, Japan), 60(24), 3849-3856. https://doi.org/10.2169/internalmedicine.7279-21
Kumei, Shinsuke, et al. "Impact of the Concomitant Use of Immunomodulator and a Lower Week 8 Partial Mayo Score on the Persistence of Adalimumab in Refractory Ulcerative Colitis." Internal medicine (Tokyo, Japan) vol. 60,24 (2021): 3849-3856. doi: https://doi.org/10.2169/internalmedicine.7279-21
Kumei S, Sakurai T, So S, Itaba S, Akiho H, Nakamura S, Kim H, Yamasaki M, Takatsu N, Maekawa R, Sakemi R, Watanabe T, Shibata M, Kume K, Yoshikawa I, Takaki Y, Harada M. Impact of the Concomitant Use of Immunomodulator and a Lower Week 8 Partial Mayo Score on the Persistence of Adalimumab in Refractory Ulcerative Colitis. Intern Med. 2021 Dec 15;60(24):3849-3856. doi: 10.2169/internalmedicine.7279-21. Epub 2021 Jun 12. PMID: 34121007.
Copy Download .nbib Format: NLM
MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma.

Oral oncology

Noji R, Kano Y, Hirai H, Onishi I, Nishii N, Yoshimura R, Miyake S, Ikeda S, Harada H.
PMID: 34896892
Oral Oncol. 2021 Dec 09;124:105666. doi: 10.1016/j.oraloncology.2021.105666. Epub 2021 Dec 09.

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) have a poor prognosis. Recently, the use of immune checkpoint inhibitors (ICIs) for drug treatment has been expanding . However, the response rate to...

Cite
Noji R, Kano Y, Hirai H, et al. MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. Oral Oncol. 2021;124:105666doi: 10.1016/j.oraloncology.2021.105666.
Noji, R., Kano, Y., Hirai, H., Onishi, I., Nishii, N., Yoshimura, R., Miyake, S., Ikeda, S., & Harada, H. (2021). MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. Oral oncology, 124105666. https://doi.org/10.1016/j.oraloncology.2021.105666
Noji, Rika, et al. "MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma." Oral oncology vol. 124 (2021): 105666. doi: https://doi.org/10.1016/j.oraloncology.2021.105666
Noji R, Kano Y, Hirai H, Onishi I, Nishii N, Yoshimura R, Miyake S, Ikeda S, Harada H. MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. Oral Oncol. 2021 Dec 09;124:105666. doi: 10.1016/j.oraloncology.2021.105666. Epub 2021 Dec 09. PMID: 34896892.
Copy Download .nbib Format: NLM
Showing 3361 to 3365 of 3365 entries